Holen Sie sich die Stockscreener-App
9.97
1.77%
-0.18
Handel nachbörslich:
10.00
0.03
+0.30%
Schlusskurs vom Vortag:
$10.15
Offen:
$10.19
24-Stunden-Volumen:
1.04M
Relative Volume:
0.84
Marktkapitalisierung:
$758.60M
Einnahmen:
$11.40B
Nettoeinkommen (Verlust:
$-95.73M
KGV:
-4.0694
EPS:
-2.45
Netto-Cashflow:
$-64.37M
1W Leistung:
+0.81%
1M Leistung:
+23.70%
6M Leistung:
+15.26%
1J Leistung:
+51.29%
1-Tages-Spanne:
$9.915
$10.37
1-Wochen-Bereich:
$9.63
$10.49
52-Wochen-Spanne:
$4.70
$10.49
Mind Medicine Inc Stock (MNMD) Company Profile
Firmenname
Mind Medicine Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MNMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
9.97 | 772.29M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Mind Medicine Inc Aktie (MNMD) Neueste Nachrichten
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - MSN
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed (MNMD) Q2 2025 Earnings Call Transcript - AOL.com
1 Reason to Buy MindMed (MNMD) - AOL.com
MindMed Reports Strong Q2 2025 Results - The Motley Fool
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) large institutional owners must be happy as stock continues to impress, up 17% over the past week - simplywall.st
Mind Medicine (MindMed) (NASDAQ:MNMD) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Using RSI to spot recovery in Mind Medicine (MindMed) Inc.Weekly Breakout Forecast with Entry Zones - Newser
What makes Mind Medicine (MindMed) Inc. stock price move sharplyFree Trade Ready Stock Watch for Short Term - Newser
MindMed Reports Strong Phase 3 Trial Progress and Leadership Appointment - The Globe and Mail
Pattern recognition hints at Mind Medicine (MindMed) Inc. upsideAlpha Generation Strategy with Low Volatility - Newser
Roth Capital Issues Pessimistic Outlook for MNMD Earnings - Defense World
What MACD signals say about Mind Medicine (MindMed) Inc.AI-Based Reversal Point Prediction Signal - Newser
What is HC Wainwright’s Forecast for MNMD FY2028 Earnings? - Defense World
Oppenheimer Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) - Defense World
Is Mind Medicine stock a buy? - Cantech Letter
Mind Medicine upgraded at Oppenheimer on lead asset - MSN
A Quick Look at Today's Ratings for Mind Medicine(MNMD.US), With a Forecast Between $18 to $55 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
MindMed Bets Big On Psychedelic Therapies With Cash To Spare - Finimize
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating - AInvest
Mind Medicine resumed with an Outperform at Oppenheimer - TipRanks
Mind Medicine’s Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Mind Medicine (MNMD) Gains Positive Outlook with Oppenheimer's O - GuruFocus
Mind Medicine (MindMed)’s (MNMD) “Buy” Rating Reiterated at Chardan Capital - Defense World
What are the latest earnings results for Mind Medicine (MindMed) Inc.Invest confidently with advanced analysis tools - Jammu Links News
Why is Mind Medicine (MindMed) Inc. stock attracting strong analyst attentionFree Trading Psychology Coaching - Jammu Links News
How does Mind Medicine (MindMed) Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
What is the dividend policy of Mind Medicine (MindMed) Inc. stockOutstanding capital returns - Jammu Links News
What analysts say about Mind Medicine (MindMed) Inc. stockAccelerate your capital gains today - Jammu Links News
Is it the right time to buy Mind Medicine (MindMed) Inc. stockHigh-yield portfolio picks - Jammu Links News
How does Mind Medicine (MindMed) Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Mind Medicine (MindMed) Inc. stock expected to show significant growthAchieve breakthrough investment performance - Jammu Links News
How volatile is Mind Medicine (MindMed) Inc. stock compared to the marketAI Powered Signals For Consistent Profits - jammulinksnews.com
MindMed (MNMD) Q2 Net Loss Jumps 625% - The Globe and Mail
MindMed Reports Strong Q2 2025 Financial Results - The Globe and Mail
Unraveling the Sharp Drop in Mind Medicine (MNMD.O): A Technical and Order-Flow Deep Dive - AInvest
Mind Medicine Inc's Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic Advancements in MM-120 ODT Trials - AInvest
Earnings call transcript: MindMed Q2 2025 reveals cash runway into 2027 - Investing.com Canada
Mind Medicine (MindMed) Q2 2025 Earnings Call Transcript - MarketBeat
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Mind Medicine Advances Phase III Trials for Anxiety and Depression Treatment, Appoints New CFO - AInvest
Real time social sentiment graph for Mind Medicine (MindMed) Inc.Market Downturn Defense Strategy Analysis - Newser
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway - Investing.com Nigeria
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway By Investing.com - Investing.com South Africa
MindMed Reports Q2 2025 Financial Results and Business Updates - Business Wire
What is the risk reward ratio of investing in Mind Medicine (MindMed) Inc. stockEntry Signal Growth Plan That Work - Jammu Links News
Finanzdaten der Mind Medicine Inc-Aktie (MNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):